SCHEMBL23217367

SCHEMBL23217367

O=COC(=O)CCCNC(=O)Nc1ccc(S(=O)(=O)N2CCN(c3cccc(C(F)(F)F)c3)CC2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.49
GAA P10253 5/20 0.49
MAPT P10636 5/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
HTT P42858 3/20 0.49
ALDH1A1 P00352 3/20 0.47
KMT2A Q03164 2/20 0.47
PTPN11 Q06124 1/20 0.46
MEN1 O00255 1/20 0.46
TRPV4 Q9HBA0 1/20 0.46
HSD17B10 Q99714 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA7 P43166 1/20 0.45
POLB P06746 1/20 0.45
F13A1 P00488 1/20 0.44
TGM2 P21980 1/20 0.44
TGM1 P22735 1/20 0.44
TP53 P04637 1/20 0.44
NAMPT P43490 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23217117 0.91 MAPT (0.53) LMNAGAAMAPTSMN1; SMN2HTT
Formic Acid SCHEMBL23217369 0.90 PTPN11 (0.54) LMNAGAAMAPTSMN1; SMN2HTT
SCHEMBL23217315 0.89 LMNA (0.52) LMNAGAAMAPTSMN1; SMN2HTT
SCHEMBL23217265 0.88 PTPN11 (0.56) LMNAGAAMAPTSMN1; SMN2HTT
SCHEMBL23217103 0.87 LMNA (0.49) LMNAGAAMAPTSMN1; SMN2HTT
SCHEMBL23217131 0.86 PTPN11 (0.55) LMNAGAAMAPTSMN1; SMN2HTT
SCHEMBL23217419 0.85 LMNA (0.49) LMNAGAAMAPTSMN1; SMN2HTT
SCHEMBL23217298 0.83 MAPT (0.46) LMNAGAAMAPTSMN1; SMN2HTT
SCHEMBL1870289 0.78 F13A1 (0.72) LMNAGAAMAPTSMN1; SMN2HTT
SCHEMBL23217100 0.77 MAPT (0.70) LMNAGAAMAPTSMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240124400-A1 LPXH TARGETING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF MAKING AND USING THE SAME DUKE UNIVERSITY (US) 2024-04-18 US disclosed
WO-2021072369-A1 LPXH TARGETING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF MAKING AND USING THE SAME DUKE UNIVERSITY (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124400-A1 LPXH TARGETING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF MAKING AND USING THE SAME CFH, LPAR3, CBR3 LMNA 512/4885GAA 4250/4885MAPT 4754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.